MAIA Biotechnology, Inc. (MAIA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

MAIA Biotechnology, Inc. (MAIA) Healthcare & Pipeline Overview

MAIA Biotechnology, Inc. is a clinical-stage biotech firm specializing in targeted cancer therapies, particularly non-small cell lung cancer, with its lead drug candidate, THIO, utilizing a unique dual mechanism of action to target telomeres and stimulate the immune system, positioning it within the competitive oncology market.

What Is the Investment Thesis for MAIA?

MAIA Biotechnology presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's valuation is approximately $60 million. The core investment thesis revolves around the successful clinical development and eventual commercialization of THIO, their lead drug candidate targeting non-small cell lung cancer. Key value drivers include positive clinical trial results demonstrating THIO's efficacy and safety, potential partnerships with larger pharmaceutical companies for late-stage development and commercialization, and expansion of THIO's application to other cancer types. A significant risk lies in the inherent uncertainty of clinical trials and regulatory approvals. Failure to achieve positive clinical outcomes or secure regulatory approval would negatively impact the company's valuation. The company's limited cash runway also poses a risk, potentially requiring additional financing that could dilute existing shareholders.

Based on FMP financials and quantitative analysis

MAIA Key Highlights

Market capitalization of $79.7M reflects its early stage and potential growth in the biotechnology sector.

• THIO, the lead asset, is currently in clinical trials targeting non-small cell lung cancer, showcasing a focused approach.
• The company's dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity offers a novel approach to cancer treatment.
• Founded in 2018, MAIA Biotechnology is still in its early stages of development, indicating significant growth potential.
• A P/E ratio of -2.28 reflects the company's current lack of profitability due to ongoing research and development expenses.

Who Are MAIA's Competitors?

MAIA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MAIA's Key Strengths?

Novel drug candidate (THIO) with a unique mechanism of action.

• Focus on a significant unmet need in cancer treatment (NSCLC).
• Experienced management team with expertise in drug development.
• Strong intellectual property protection for THIO.

What Are MAIA's Weaknesses?

Early-stage clinical development with significant regulatory risk.

• Limited financial resources and reliance on external funding.
• Small company size with limited infrastructure and resources.
• Dependence on the success of a single drug candidate.

What Could Drive MAIA Stock Higher?

MAIA catalyst: Announcement of Phase 2 clinical trial results for THIO in non-small cell lung cancer (NSCLC) expected in late 2026.

• Enrollment of patients in ongoing clinical trials for THIO.
• FDA grants Breakthrough Therapy designation for THIO, potentially accelerating regulatory review.
• Strategic partnership or licensing agreement with a major pharmaceutical company.

What Are the Key Risks for MAIA?

Financial-distress signal — its Altman Z-Score of -1.99 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure to achieve positive clinical trial results for THIO.
• Regulatory setbacks or delays in the approval process.
• Competition from established pharmaceutical companies and other biotechnology firms developing cancer therapies.
• Dependence on securing additional funding to support clinical development and operations.
• Intellectual property challenges or infringement.

What Are the Growth Opportunities for MAIA?

• Expansion into Additional Cancer Types: THIO's mechanism of action, targeting telomeres and enhancing immunogenicity, has the potential to be effective in treating other types of cancer beyond non-small cell lung cancer. Exploring and initiating clinical trials for indications such as breast cancer, prostate cancer, or ovarian cancer could significantly expand MAIA's market opportunity. Each new indication represents a potential multi-billion dollar market, offering substantial revenue growth if THIO proves effective. This expansion could begin within the next 2-3 years, contingent on positive initial trial results.
• Strategic Partnerships with Pharmaceutical Companies: Partnering with larger pharmaceutical companies for late-stage clinical development and commercialization could provide MAIA with access to significant financial resources, expertise, and established distribution networks. Such partnerships can accelerate the development and commercialization of THIO, increasing its market penetration and revenue potential. These partnerships could involve licensing agreements, co-development agreements, or even acquisition. The timeline for securing such partnerships is uncertain but could materialize within the next 1-2 years following positive Phase 2 trial data.
• Accelerated Regulatory Pathways: Obtaining accelerated regulatory approval pathways, such as Breakthrough Therapy designation or Fast Track designation from the FDA, could expedite the review and approval process for THIO. These designations are granted to drugs that demonstrate the potential to address unmet medical needs in serious conditions. Receiving such designations could shorten the time to market for THIO and provide a competitive advantage. The application for these designations can be submitted after promising Phase 2 data, potentially leading to accelerated approval within 2-3 years.
• Geographic Expansion: Expanding clinical trials and eventual commercialization efforts into new geographic markets, such as Europe and Asia, could significantly increase MAIA's market reach and revenue potential. These markets represent substantial opportunities for cancer therapies, particularly in countries with aging populations and increasing cancer incidence rates. Establishing partnerships with local distributors and regulatory experts will be crucial for successful geographic expansion. This expansion could commence within 3-5 years following initial commercialization in the United States.
• Development of Companion Diagnostics: Developing companion diagnostics to identify patients most likely to respond to THIO could improve treatment outcomes and increase its market adoption. Companion diagnostics can help personalize treatment decisions and ensure that THIO is used in patients who are most likely to benefit. This approach can enhance the value proposition of THIO and differentiate it from other cancer therapies. The development of companion diagnostics could begin in parallel with Phase 3 clinical trials, with potential availability within 3-4 years.

What Are MAIA's Competitive Advantages?

• Proprietary drug candidate (THIO) with a unique dual mechanism of action.
• Patent protection for THIO and its applications.
• Clinical data demonstrating THIO's efficacy and safety.
• Expertise in telomere targeting and cancer immunotherapy.

What Does MAIA Do?

MAIA Biotechnology, Inc., founded in 2018 and headquartered in Chicago, Illinois, is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative cancer therapies. The company's primary focus is on addressing unmet needs in the treatment of cancer, particularly non-small cell lung cancer (NSCLC). Their lead asset, THIO (also known as 6-thio-dG or 6-thiodeoxyguanosine), is an investigational drug candidate with a dual mechanism of action. THIO is designed to selectively target telomeres in cancer cells, disrupting their ability to replicate and proliferate uncontrollably. Simultaneously, it enhances the immunogenicity of cancer cells, making them more susceptible to recognition and destruction by the patient's immune system. MAIA Biotechnology is currently focused on advancing THIO through clinical trials, with the goal of demonstrating its safety and efficacy in treating NSCLC and potentially other types of cancer. The company's strategy involves leveraging THIO's unique mechanism of action to overcome resistance to existing therapies and improve patient outcomes. MAIA Biotechnology operates with a lean organizational structure, comprising 13 employees, enabling agility and focused execution of its clinical development programs.

What Products and Services Does MAIA Offer?

• Develops therapies targeting cancer.
• Focuses primarily on non-small cell lung cancer.
• Discovers and commercializes cancer treatments.
• Utilizes a dual mechanism of action drug candidate.
• Targets telomeres in cancer cells.
• Enhances the immunogenicity of cancer cells.
• Conducts clinical trials to evaluate drug safety and efficacy.

How Does MAIA Make Money?

• Develops and patents novel cancer therapies.
• Out-licenses or partners with larger pharmaceutical companies for commercialization.
• Generates revenue through milestone payments and royalties on sales of approved drugs.

What Industry Does MAIA Operate In?

MAIA Biotechnology operates within the competitive biotechnology industry, specifically targeting the oncology market. The industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for cancer therapies is substantial and growing, driven by an aging population and increasing cancer incidence rates. MAIA's focus on non-small cell lung cancer positions it within a significant segment of the oncology market. Competitors include established pharmaceutical companies and other biotechnology firms developing novel cancer therapies. The company's success will depend on its ability to differentiate THIO from existing treatments and demonstrate its clinical efficacy and safety.

Who Are MAIA's Key Customers?

• Patients diagnosed with cancer, particularly non-small cell lung cancer.
• Oncologists and other healthcare professionals who treat cancer patients.
• Hospitals and cancer centers that provide cancer treatment services.

Over the past six months, MAIA Biotechnology, Inc. insiders filed 25 SEC Form 4 transactions — 0 sales and 25 purchases. On net that is roughly 3.1M shares acquired (about $4.2M) — insiders putting money in tends to read as conviction.

MAIA Biotechnology, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 15.4% above estimates on average.

MAIA Biotechnology, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.99 places it in the distress zone, a signal of elevated financial risk.

Key Financial Metrics

Return on assets is -68.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -23.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.59 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -53.4%, the inverse of the P/E and a quick read on earnings relative to price.

MAIA Biotechnology, Inc. (MAIA) Valuation Context

Valued at $79.7M, MAIA is classified as a micro-cap stock. Relative to its peer group, MAIA's quantitative score of 29/100 is below the peer average of 66/100.

MAIA Revenue & Earnings Trend

In Q2 FY2026, MAIA generated $0 in top-line revenue. The company recorded a net loss of $7.9M, with diluted EPS of $-0.13. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, MAIA averaged $-0.18 in diluted EPS.

Company Profile

MAIA Biotechnology, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Chicago, US. The company is led by CEO Vlad Vitoc. MAIA has traded publicly since 2022.

MAIA Financials

MAIA Latest News

MAIA Analyst Consensus

MAIA MoonshotScore

Common Questions About MAIA (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources